NouvNeu001 is a cell replacement therapy for Parkinson's disease (PD) that uses human dopaminergic progenitor cells derived from stem cells. The therapy aims to restore dopamine production in the brains of patients with mid- to late-stage Parkinson's disease by transplanting dopaminergic neurons that can integrate into the existing neural circuitry and produce dopamine.
Trial Details
...
Overview
Mermaid diagram (expand to render)
NouvNeu001 is a cell replacement therapy for Parkinson's disease (PD) that uses human dopaminergic progenitor cells derived from stem cells. The therapy aims to restore dopamine production in the brains of patients with mid- to late-stage Parkinson's disease by transplanting dopaminergic neurons that can integrate into the existing neural circuitry and produce dopamine.
Trial Details
| Parameter | Value | |-----------|-------| | NCT Number | NCT06167681 | | Status | Recruiting | | Phase | Phase I/II | | Sponsor | iRegene Therapeutics Co., Ltd. | | Intervention | NouvNeu001 (human dopaminergic progenitor cells) | | Route | Intracerebral injection | | Enrollment | 40 participants (estimated) | | Start Date | January 17, 2024 | | Completion Date | July 2029 | | Locations | Beijing, China; Wuhan, China |
Mechanism of Action
NouvNeu001 represents a cell replacement therapy approach that addresses the core pathological feature of Parkinson's disease — the progressive loss of dopaminergic neurons in the substantia nigra pars compacta.
Cell Therapy Mechanism
Dopaminergic Progenitor Cells — NouvNeu001 consists of human dopaminergic progenitor cells that are programmed to develop into mature dopamine-producing neurons
Cell Transplantation — Cells are injected directly into the brain regions affected by dopamine loss (typically the striatum or substantia nigra)
Neuronal Integration — The transplanted cells can potentially:
Extend axons to target regions
Form functional synaptic connections
Integrate into existing neural circuits
4. Dopamine Production — Mature dopaminergic neurons produce and release dopamine, restoring the neurotransmitter deficiency that causes motor symptoms
Rationale for Cell Replacement
The loss of dopaminergic neurons in Parkinson's disease leads to:
While current treatments like levodopa (a dopamine precursor) and deep brain stimulation manage symptoms, they do not address the underlying neuronal loss. Cell replacement therapy aims to:
Allogeneic (Off-the-Shelf) — Can be produced in bulk and stored, allowing for immediate treatment when needed
Standardized Manufacturing — Consistent product quality through GMP production
Reduced Patient Burden — No need for extended cell culture period (unlike iPSC approaches)
Established Safety Profile — Being evaluated in Phase I/II trials
Preclinical Evidence
Cell replacement therapy for PD has a long history, with preclinical and clinical evidence supporting the approach:
Animal Models
Non-human primate studies: Demonstrated that transplanted dopaminergic neurons can survive, integrate, and improve motor function in parkinsonian primates
Rodent studies: Showed proof of concept for dopamine production and functional recovery
Historical Clinical Evidence
Fetal tissue transplants (1980s-1990s): Showed some patients experienced significant improvement, but results were variable and the approach was discontinued due to ethical concerns and inconsistent outcomes
Modern cell therapy: Newer approaches using ESC and iPSC derivatives have shown promise in early-phase clinical trials
Study Design
Phase I/II Trial (NCT06167681)
Primary Objectives:
Assess safety and tolerability of NouvNeu001 injection
Evaluate efficacy through motor function assessments
Key Endpoints:
Adverse events (safety monitoring)
Motor function improvement (UPDRS scores)
Quality of life measures
Inclusion Criteria (typical for PD cell therapy trials):
Diagnosis of idiopathic Parkinson's disease
Mid- to late-stage disease
On/off fluctuations or inadequate response to standard therapy
Safety Considerations
Potential Risks
Intracranial Hemorrhage — Risk from the surgical procedure of cell injection
Infection — Any brain surgery carries infection risk
Immunological Rejection — Allogeneic cells may be recognized as foreign
Dyskinesias — Abnormal involuntary movements, observed in some historical transplant trials
Tumor Formation — Theoretical risk with any cell therapy, though considered low with progenitor cells
Graft Failure — Cells may not survive or integrate properly
Risk Mitigation
Careful surgical technique
Immunosuppressive therapy as needed
Rigorous cell characterization and quality control
Close monitoring during follow-up
Significance for Parkinson's Disease
NouvNeu001 represents an important step in the development of disease-modifying therapies for Parkinson's disease:
Addresses Root Cause — Unlike symptomatic treatments, cell replacement aims to replace lost neurons
Potential for Long-Term Benefit — Single treatment could provide years of benefit
Advances Cell Therapy Field — Contributes to understanding of optimal cell delivery and integration
[Unknown, Cell therapy for Parkinson's disease: current state and future directions - npj Parkinson's Disease (n.d.)](https://doi.org/10.1038/s41531-021-00203-9)
[Unknown, iPSC-derived dopamine neurons for Parkinson's disease - Nature (n.d.)](https://doi.org/10.1038/nature20491)
Pathway Diagram
The following diagram shows the key molecular relationships involving NouvNeu001 Cell Therapy for Parkinson's Disease discovered through SciDEX knowledge graph analysis: